How to take Enasidenib

The U.S. Food and Drug Administration (FDA)introduced ensidipine (Enasidenib) as an anticancer agent developed as the first selective allosteric inhibitor of a tumor target (i.e.IDH2) in relapsed or refractory acute myeloid leukemia. The overall survival rate in the phase 1/2 clinical trial of ensidipine was 40.3%, and the complete response rate was 19.3%.

Assess blood counts and blood chemistries for leukocytosis and tumor lysis syndrome before initiating ensidipine and monitor at least every 2 weeks for at least the first 3 months of treatment. Handle any abnormal situations promptly. The recommended dose of ensidipine is 100 mg taken orally once daily with or without food until disease progression or unacceptable toxicity occurs. For patients without disease progression or unacceptable toxicity, treat for at least 6 months to allow time for clinical response. In patients who develop leukocytosis (white blood cell count> 30,000/mm3) in the absence of infection, initiate hydroxyurea therapy according to standard practice. If leukocytosis persists, temporary interruption of ensidipine therapy may be necessary.

Ensiidi plain investigational medicine is not currently on the market in the country, nor is it covered by medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic encidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*60 tablets produced by a Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of the original encidipine generic drug.